caa a22 4500 445794488 CHVBK 20180317145120.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10620-011-1877-6 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1877-6 Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database [Elektronische Daten] [Sunanda Kane, Michael Sumner, Dory Solomon, Matthew Jenkins] Background: Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration. Aim: To evaluate persistency in patients receiving various oral 5-ASA formulations. Methods: This retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA [Lialda®, Asacol®, Pentasa® 250 or 500mg, balsalazide (generic and Colazal®), and olsalazine (Dipentum®)] between March and September 2007. Persistency was evaluated monthly on the basis of prescription refill rates. Results: Prescription and refill records were identified for 44,191 patients receiving oral 5-ASA. After 1year, 20% of patients receiving Lialda were considered persistent and classified as continuing (refilling within a timeframe of up to twice the duration of the prescription), compared with 9% receiving Asacol, 7 (250mg) and 10% (500mg) receiving Pentasa, 10% receiving balsalazide, and 10% receiving Dipentum. Conclusions: Overall persistency with oral 5-ASA therapy was low. However, patients receiving once-daily Lialda had significantly higher persistency after 1year of treatment than patients receiving other oral 5-ASA therapies. Springer Science+Business Media, LLC, 2011 5-aminosalicylic acid nationallicence Mesalazine nationallicence Mesalamine nationallicence Persistency nationallicence Ulcerative colitis nationallicence Pharmacy database nationallicence Kane Sunanda Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, 55905, Rochester, MN, USA aut Sumner Michael Shire Pharmaceuticals Inc., Wayne, PA, USA aut Solomon Dory Shire Pharmaceuticals Inc., Wayne, PA, USA aut Jenkins Matthew Shire Pharmaceuticals Inc., Wayne, PA, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3463-3470 0163-2116 56:12<3463 2011 56 10620 https://doi.org/10.1007/s10620-011-1877-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1877-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kane Sunanda Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Sumner Michael Shire Pharmaceuticals Inc., Wayne, PA, USA aut NATIONALLICENCE 700 1- Solomon Dory Shire Pharmaceuticals Inc., Wayne, PA, USA aut NATIONALLICENCE 700 1- Jenkins Matthew Shire Pharmaceuticals Inc., Wayne, PA, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3463-3470 0163-2116 56:12<3463 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer